Immunome, a preclinical biotech developing antibody therapies for cancer and infectious diseases, raised $39 million by offering 3.3 million shares at $12, within the range of $11 to $13. The company offered 0.8 million more shares than anticipated. At pricing, the company raised 30% more in proceeds than expected.
Immunome plans to list on the Nasdaq under the symbol IMNM. Ladenburg Thalmann and Chardan Capital Markets acted as joint bookrunners on the deal.
Preclinical oncology biotech Immunome prices upsized IPO at $12 midpoint
October 2, 2020

